<div id="readability-page-1"><p><span>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report)</span> had its price target raised by stock analysts at Bank of America  from $21.00 to $22.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has an &#34;underperform&#34; rating on the stock. Bank of America's price target would indicate a potential downside of 36.56% from the company's current price.</p><div><p><span></span><span>Get <strong>Hims &amp; Hers Health</strong> alerts:</span></p></div><ul><li>Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?</li></ul><p>A number of other equities research analysts also recently issued reports on HIMS. Truist Financial lifted their price target on shares of Hims &amp; Hers Health from $24.00 to $39.00 and gave the company a &#34;hold&#34; rating in a research report on Wednesday, February 26th. Leerink Partners increased their price objective on Hims &amp; Hers Health from $24.00 to $40.00 and gave the company a &#34;market perform&#34; rating in a research note on Tuesday, February 25th. Needham &amp; Company LLC lifted their price objective on Hims &amp; Hers Health from $31.00 to $61.00 and gave the stock a &#34;buy&#34; rating in a research report on Tuesday, February 25th. Citigroup  restated a &#34;sell&#34; rating and issued a $27.00 target price on shares of Hims &amp; Hers Health in a report on Thursday, March 6th. Finally, Canaccord Genuity Group lifted their price target on shares of Hims &amp; Hers Health from $38.00 to $68.00 and gave the stock a &#34;buy&#34; rating in a report on Wednesday, February 19th. Two equities research analysts have rated the stock with a sell rating, seven have assigned  a hold rating and six have assigned  a buy rating to the company. Based on data from MarketBeat, the stock  has a consensus rating of &#34;Hold&#34; and an average price target of $37.31.</p><p><b>View Our Latest Stock Report on Hims &amp; Hers Health</b></p><h2>Hims &amp; Hers Health Stock Up 4.6 %</h2><ul><li>Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors</li></ul><p>HIMS opened at $34.68 on Tuesday. The business has a 50 day moving average price of $38.64 and a two-hundred day moving average price of $28.37. Hims &amp; Hers Health has a 52 week low of $11.20 and a 52 week high of $72.98. The company has a market cap of $7.70 billion, a PE ratio of 78.82 and a beta of 1.37. </p><p>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.09 by $0.02. Hims &amp; Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million.  As a group, sell-side analysts expect that  Hims &amp; Hers Health will post 0.29 EPS for the current fiscal year. </p><h2>Insider Transactions at Hims &amp; Hers Health</h2><ul><li>MarketBeat Week in Review – 03/03 - 03/07</li></ul><p>In related news, insider Soleil Boughton sold 268,932 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $27.75, for a total value of $7,462,863.00. Following the completion of the sale, the insider now directly owns 169,803 shares in the company, valued at approximately $4,712,033.25. This represents a 61.30 % decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, CEO Andrew Dudum sold 36,460 shares of the business's stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $27.09, for a total value of $987,701.40. Following the transaction, the chief executive officer now owns 27,918 shares in the company, valued at approximately $756,298.62. This represents a 56.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 890,592 shares of company stock valued at $31,677,291 over the last 90 days. Corporate insiders own  17.71% of the company's stock. </p><h2>Institutional Trading of Hims &amp; Hers Health</h2><p>Several large investors have recently bought and sold shares of HIMS. Crewe Advisors LLC purchased a new position in shares of  Hims &amp; Hers Health in the fourth quarter valued at $28,000.  Raleigh Capital Management Inc. lifted its holdings in  Hims &amp; Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after buying an additional 1,100 shares in the last quarter.  Blume Capital Management Inc. boosted its position in  Hims &amp; Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after buying an additional 600 shares during the last quarter.  Smartleaf Asset Management LLC grew its stake in shares of  Hims &amp; Hers Health by 4,415.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after acquiring an additional 1,413 shares in the last quarter.  Finally, Summit Securities Group LLC purchased a new stake in shares of  Hims &amp; Hers Health during the fourth quarter worth about $38,000. Institutional investors and hedge funds own  63.52% of the company's stock. </p><h2>About Hims &amp; Hers Health</h2> (Get Free Report)<p>Hims &amp; Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA. </p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Hims &amp; Hers Health</li><li>Basic Materials Stocks Investing</li><li>Joby Aviation Stock: Virgin Atlantic Deal Signals Big Potential</li><li>What is the Hang Seng index?  </li><li>Kohl’s Posts Another Kitchen Sink Quarter, But New CEO Has a Plan</li><li>What Are Some of the Best Large-Cap Stocks to Buy?</li><li>Southwest Airlines Could Triple From Here—Here's How</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Hims &amp; Hers Health Right Now?</h2><p>Before you consider Hims &amp; Hers Health, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims &amp; Hers Health wasn't on the list.</p><p>While Hims &amp; Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

HIMS

<p>Bank of America has raised its price target for Hims & Hers Health (NYSE:HIMS) from $21.00 to $22.00, maintaining an "underperform" rating. This new target suggests a potential downside of 36.56% from the current price. Other analysts have varied opinions, with price targets ranging from $24.00 to $68.00. Hims & Hers Health's stock opened at $34.68, with a market cap of $7.70 billion and a PE ratio of 78.82. The company reported $0.11 EPS for the last quarter, exceeding estimates.</p>

Hims & Hers Health (NYSE:HIMS) Given New $22.00 Price Target at Bank of America